Page last updated: 2024-11-03

risperidone and Leukoencephalopathy Syndrome, Posterior

risperidone has been researched along with Leukoencephalopathy Syndrome, Posterior in 1 studies

Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Joshi, S1
Krstacic, J1
Mallangada, N1
Coriolan, S1
Karampahtsis, C1

Other Studies

1 other study available for risperidone and Leukoencephalopathy Syndrome, Posterior

ArticleYear
    Journal of child and adolescent psychopharmacology, 2020, Volume: 30, Issue:10

    Topics: Child; Delirium; Electroencephalography; Humans; Induction Chemotherapy; Magnetic Resonance Imaging;

2020